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Background: Single-arm trial (SAT) data is increasingly reviewed for drug approvals by regulators and Health Technology
Assessment (HTA) bodies. Supplementary data in the form of external comparators (ECs) can be used to provide clinical
context to support these drug evaluations. In this study we characterized HTAs for SAT-based submissions, the use of
supplementary EC data and outcomes from HTA review.
Methods: HTA Accelerator database was used to describe SAT-based HTA submissions with decisions (2011-2019).
Results: A total of 433 SAT-based HTA submissions were identified between 2011 and 2019 with a 13-fold increase during this
period. Around 65%(283/433) were in oncology or hem-oncology. Around 52%(226/433) of submissions contained some type
of EC data, including prior clinical trials (24%, 104) and real-world data (RWD) (20%, 87), but 40%(175) contained no EC data.
The overall acceptance rate for SAT-based submissions was 48% and with RWD EC data acceptance was 59%. In the latest 5-
year period (2015-2019), use of RWD ECs increased 22% as a proportion of submissions per year, whereas, prior trial ECs
decreased (–14%) and use of no EC remained stable (–2%). Between 2015 to 2017 and 2018 to 2019, acceptance rate for
RWD ECs increased by 20% (41% in 2015-2017 to 61% in 2018-2019) whereas prior trial EC use decreased by 10% and no
EC submissions decreased 16%. Of 226 submissions using ECs, only 29%(66) used an adjusted indirect treatment
comparison method.
Conclusions: SAT-based submissions to HTA bodies are rapidly evolving in terms of composition and acceptance. Types of EC
and methodological approach used are important determinants of positive outcomes.
Keywords: external comparators, health technology assessment, historical comparators, real-world data, synthetic
comparators.
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Randomized controlled trials (RCTs) are generally considered
the gold standard evidence for marketing authorization by regu-
latory and Health Technology Assessment (HTA) bodies1-3.
However, new drug development is increasingly focused on rare
diseases and highly targeted patient populations, where tradi-
tional RCTs, controlled against placebo or standard of care, can
present ethical and practical challenges.1,2,4,5 Additionally, earlier
phase trials may establish beyond clinical doubt that patients
would benefit from the new treatment. In these circumstances
non-RCT designs such as single-arm or multi-arm-uncontrolled
studies, switchover studies or real-world studies6-8 can be used.
Regulatory bodies have recognized the need for faster access to
treatments in under-served patient populations. According to a
recent review of European Medicines Agency (EMA) and United
States Food and Drug Administration (FDA) submission,8 most15 - see front matter Copyright ª 2021, ISPOR–The Professional Society for
cess article under the CC BY-NC-ND license (http://creativecommons.org/licnon-RCT development programs contained single-arm trial (SAT)
designs. The EMA issued 795 and the FDA 774 SAT-based drug
approvals between 1999 and 2014, with 44 and 60 respectively
based solely on SAT evidence.9,10 In an analysis of 253 United
States FDA approvals issued between 2015 to 2017, 18% of the
products had a pivotal trial with no comparator.11
This absence of internal controls in the evidence package is a
challenge to HTA bodies, which generally prefer evidence from
RCTs to determine the magnitude of benefit of a new product over
standard of care.3,12 When there is no direct comparison of
products conducted within RCTs, multiple RCTs can be combined,
and ‘anchored’ indirect treatment comparisons can be made using
network meta-analysis methods.13 When RCTs are not available,
methods for ‘unanchored’ meta-analysis can still be used, such as
matching-adjusted indirect comparisons (MAIC) and simulated
treatment comparisons (STC).14-16 When patient level data is
available, more direct comparison methods can be applied such asHealth Economics and Outcomes Research. Published by Elsevier Inc. This is an
enses/by-nc-nd/4.0/).
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selection bias and differences between comparator cohorts.17-19
Some formal HTA guidance is available on these approaches, and
their limitations from National Institute for Health and Care Ex-
cellence’s (NICE) decision support unit.20,21 In general, unan-
chored comparisons are less well established than anchored
methods, and additional care is needed on interpretation.12,22,23
External comparator (EC) data (also referred to as “external con-
trols,” “historical comparators,” or “synthetic controls”) collected
from patient cohorts outside of the clinical study, or “index study” is
being used more frequently to provide contextual information on a
product’s clinical efficacy, safety, and cost-effectiveness. Here patient
selection criteria from the index study protocol are applied to the
external data source (to the extent possible) so that the comparator
population looks as similar as possible to the index study popula-
tion.12,24 This type of supplementary dataset can be used for naive
(unadjusted comparison) or adjusted indirect treatment comparison
using STC or MAIC approaches.
To describe the landscape forHTA submissionson the basis of SAT
data; theuseof ECs in this contextand their impactonHTAoutcomes,
we used IQVIA’s HTA Accelerator platform to evaluate HTA reports
from 100 HTA agencies across 40 countries published since 2011.
Methods
Database Overview
We performed a retrospective descriptive analysis using the
IQVIA HTA Accelerator (www.iqvia.com/landing/hta-accelerator),
which contains over 33 000 HTA publications covering 40 coun-
tries and 100 HTA bodies published since 2011. Data in HTA
Accelerator comes from submissions, which are tracked in local
language by market access experts who identify, translate and
summarize new reports, and update existing reports when new
information is available. Each report is captured and curated by
analysts into a framework of 250 available data elements that
includes indication, clinical evidence and comparators, economic
analysis, HTA body critique, and recommendations. Internal
workflows separate the data entry from quality review, with re-
view being performed by senior team members. Automated logic
checks are in place to further enhance database quality.
HTA outcomes were categorized as “positive” (including posi-
tive with restrictions), “negative,” “no recommendation,” or
“multiple recommendations” (see Appendix Table 1 in Supple-
mental Materials found at https://doi.org/10.1016/j.jval.2021.01.
015 for outcomes definitions). Positive and restricted positive
recommendations were grouped for the purposes of outcomes
analysis. One exception was for Haute Autorité de Santé (HAS)
submissions in France where Amélioration du Service Médical
Rendu (ASMR) V ratings were classified as negative recommen-
dation (see Appendix Table 2 in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2021.01.015 for ASMR definitions).
This rating indicates no added product benefit, and while products
will still be reimbursed, subsequent price negotiations are
affected. In Germany, Gemeinsamer Bundesausschuss (G-BA) no
added benefit is automatically classified as a negative
recommendation.
Datapoints were captured in addition to the standard HTA
Accelerator dataset for this study. We categorized the type of EC
as: (1) real-world data (RWD), with sub-categories as follows:
registry, database study, chart review, and undefined RWD study;
(2) prior trial; (3) RWD and prior trial; (4) unclear (including early
access program data or expert opinions only); and (5) no EC. We
considered all 5 categories mutually exclusive for this analysis but
recognize that there are overlaps and that to fully describe theRWD study design, further details would be necessary. This was
considered outside the scope of this analysis. Category 2 (prior
trial), refers to cases where manufacturers employ either the
active or control arm data from prior RCTs to compare with SAT
data.
For each comparator data type, the method used for indirect
treatment comparison (ITC) was classified as ‘naive’ (defined as
side-by-side comparison with or without a statistical test) or
‘adjusted’ (when statistical adjustments were made to the match
comparator population baseline characteristics - eg, MAIC, pro-
pensity scoring, or STC), where possible. We identified reports
where these methods were used by searching the text for related
terms and reviewing the context within reports.
HTA Submission Selection
HTA submissions were selected where a SAT was identified as
the main type of evidence evaluated and any submissions with
RCT evidence type were excluded. The data collection period was
January 2011 to December 2019 based on the HTA decision pub-
lication date and only submissions where the HTA decision was
available were selected. HTAs of first launch (original); label ex-
tensions as well as resubmissions, as they are known to contain
new evidence, were included. Other types of submissions (re-
newals, change in formulation submissions, or unspecified type)
were excluded from this analysis as they typically do not include
any new data (see Appendix Table 3 in Supplemental Materials
found at https://doi.org/10.1016/j.jval.2021.01.015 for a flow-chart
describing case selection). HTA bodies that do not publish their
appraisals would not be captured in this dataset. We found 433
HTA submissions fitting the study criteria from 21 countries
(Appendix Table 4 in Supplemental Materials found at https://doi.
org/10.1016/j.jval.2021.01.015).
We then created a reference set of HTA submissions as a broad
comparison dataset, which contained evidence packages on the
basis of all study-types including RCTs and non-RCT, with
matching submission type and countries (Appendix Table 3 in
Supplemental Materials found at https://doi.org/10.1016/j.jval.2
021.01.015).
Data Analyses
Descriptive statistics were presented for overall SAT sub-
missions per year and by therapy area. Submission characteristics
were presented by type of supplementary or EC data and by HTA
outcomes. Trends in HTA outcomes were analysed over the latest
5-year period, 2015 to 2019 by comparing decisions in between
time period 2015 to 2017 and 2018 to 2019.
This analysis was further broken down by HTA for the Top 5
HTA bodies by submission volume covering pan-Canadian
Oncology Drug Review (pCODR) or Canadian Agency for Drugs
and Technologies in Health (CADTH), Frances’ HAS, United King-
dom’s NICE, Germany’s G-BA and Australia’s Pharmaceutical
Benefits Advisory Committee (PBAC). Descriptive analysis was
provided on the proportion of naive and adjusted statistical
methods used for comparison by the EC category.Results
Dataset Overview
We identified and reviewed 433 SAT-based HTA submissions
(original, label extension or resubmissions) with HTA decisions
available. This represented only 5% of the total submission volume
between 2011 and 2019, but see a significant year-on-year in-
crease from 8 to 102 over this period (Fig. 1). These 433
Figure 1. Single arm trial submissions to HTA bodies; Globally, 2011-2019.
-- 3submissions represented 166 individual drug/indication combi-
nations with 65%(283/433) of submissions being for oncology or
hemato-oncology indications. The next most frequent therapy
areas were immune and/or blood disorders, endocrine and/or
metabolic and infectious diseases (10%, 9% and 8%, respectively).
90(54%) of products/indication combinations were only submitted
to one HTA body in a single country, 44(27%) recorded 2 to 4
different HTA submissions and 32(19%) recorded over 5
submissions.
Of the 40 countries covered in the HTA Accelerator platform,
SAT-based HTA submissions were identified in 21 different coun-
tries with the top 5 being Canada (17%), France (16%), United
Kingdom (15%), Germany (12%) and Australia (8.5%) (see
Supplementary Table 4 in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2021.01.015 for full list).
This set of SAT-based submissions represented 275 (65%)
original submissions, 126 (29%) for label extensions, and 32 (7%)
resubmissions. Note this includes cases of multiple submissions to
the same HTA body including an initial submission, then further
resubmissions, possibly with additional datasets after feedback
from the original submission.
Orphan drug designation and regulator conditional approval
status was available for United States FDA and EMA countries,
and accounts for 310 of the 433 SAT-based HTA submissions were
identified. We found that 44% (137) included orphan drugs, with
82% (113) being for oncology indications. Across all oncology HTA
submissions in these countries, 60% had orphan drug status. In
addition, 33% (101/310) submissions were for drugs given a
regulatory conditional approval and again nearly all (93%, 94)
were for oncology indications. Notably, 50% (94/187) of all the
SAT-based HTA submissions in oncology indications were
conditionally approved by EMA or FDA. Non-orphan drug and
conditional approval status were related, with 54% (74/137) of
orphan drugs receiving the conditional approval of the regulatorand only 16% (27/173) of non-orphan drugs receiving the con-
ditional approval.
Types of ECs used in SAT Packages
Overall, 52.2% (226/433) of SAT submissions contained some
type of supplementary dataset that can be designated as an EC.
Based on information available, ECs were most often from prior
clinical trials (24.0%, 104), then RWD (20.0%, 87), or both (8.1%, 35)
(Table 1). We find that 40.4% (175) of submissions had no EC data.
Finally, 7.4% (32) of submission packages contained supplemen-
tary evidence that was unclear, originating from expanded access
programs, or based on expert opinion. Where we found ECs based
on RWD only, details on the type of RWD source were determined
to the possible extent. Of the 87 RWD ECs, 23(26.4%) were found
to be database studies, 24 (27.5%) were registries, 3 (3.4%) were
chart reviews, and the remaining 37 (42.5%) were of unclear
design.
Trends in use of ECs were assessed over a 5-year period from
2015 to 2019. We see a 22% increase in the use of RWD-based ECs
in this period (8%-30% - as a proportion of total SAT submissions
per year). In contrast, use of prior clinical trials as ECs decreased
14% (from 33% to 17%). Overall, the use of ECs (RWD, prior clinical
trials, or both) increased marginally (16%) and the proportion of
submissions with no EC remained relatively consistent (–2%) over
the 5-year period.HTA Outcomes Based on the Type of EC
Among the 433 HTA submissions on the basis of SAT data,
48%(208) received positive recommendations, including 33% (68/
208) positive with restrictions. HTA submissions which included
EC data received a positive recommendation in 52% (118/226) of
the cases compared with 43% (75/175) with no EC.
Table 1. External comparator use and outcomes for single-arm trial based HTA submissions.
Source of comparator data Recommendation/outcome (% of row total) Total
Multiple Negative* No Rec Positive
External comparator
Real world data (including registries, database or chart review studies) - 26 (30%) 10 (11%) 51 (59%) 87
Prior clinical trial(s) - 30 (29%) 23 (22%) 51 (49%) 104
Prior clinical trial(s) and real world data - 12 (34%) 7 (20%) 16 (46%) 35
Unclear (including expanded access and expert opinion) 1 (3%) 13 (41%) 3 (9%) 15 (47%) 32
None 3 (2%) 73 (42%) 24 (14%) 75 (43%) 175
Grand Total 4 (1%) 154 (36%) 67 (15%) 208 (48%) 433
Reference:
All Submissions
720 (0.2%) 2741 (33%) 60 (0.7%) 5559 (66%) 8380
*HAS ASMR V classed as a negative outcome.
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which contained ECs based on RWD had most positive recom-
mendations (59%, 50/87) followed by submissions with prior trial
ECs (49%, 51/104). As a broad reference baseline, the HTA accep-
tance rate was 66%(5559/8380) for all HTA submissions, including
RCT-based submissions for the same set of countries covering the
same time period. Additionally, we found rates of acceptance of
SAT-based submissions between categories of ECs were broadly
consistent across the 3 major disease areas by volume (oncology,
blood and/or immune, and endocrine and/or metabolic).
Trends in HTA outcomes were analyzed over the latest 5-year
period, 2015 to 2019 by comparing decisions between time
period 2015 to 2017 and 2018 to 2019 (Appendix Table 5 in Sup-
plemental Materials found at https://doi.org/10.1016/j.jval.2021.01.
015). Acceptance rate for RWD ECs increased 120% (41% in 2015-
2017 to 61% in 2018-2019) whereas acceptance rate decreased for
prior trial by -10% (54%-44%) and no EC by -15.5% (49.4%-33.9%).
Outcomes for SAT HTA Submissions for Key HTA Bodies
To understand the outcomes at individual HTA level, we
reviewed comparator types and outcomes for the following key
decision-making bodies: HAS, France (69); PBAC, Australia (37);
G-BA, Germany (32); NICE, England (24); and pCODR/CADTH,
Canada (33).
Among these HTA bodies, only NICE showed substantially
more positive than negative recommendations (83%, 20 vs 17%,4)
(Fig. 2). This is in line with the overall acceptance rate for NICE
which is 85%. Importantly 80% (16/20) of NICE positive decisions
for SAT-based submissions had restricted access with 11 cases
controlled through the cancer drug fund. In other HTA bodies,
positive recommendation rates were only marginally higher than
negative recommendations. The proportion of positive accep-
tances with restrictions were lower for G-BA (21%, 4/19), pCODR/
CADTH (23%, 5/22), and PBAC (38%, 6/16). In France, HAS received
most SAT-based submission of all HTA bodies, as it reviews the
broadest range of products of all HTAs along with pCODR/CADTH.
For HAS, we find 36% positive outcomes for SAT-based sub-
missions and 61% were negative. However, of these negative de-
cisions, 76% (32/42) were classified as ASMR V, which allows for
reimbursement negotiations where the product is considered to
add no benefit over available current treatments.
When assessing outcomes by the type of comparator, we find
that RWD and prior clinical trial ECs were more often found as
part of positive submissions than negative ones in Canada, United
Kingdom, Germany, and France. Only in Australia, we found higher
number of RWD comparators in submissions with negativeoutcomes. However, interpretation should be cautioned as sample
size is small when analyzing individual HTA bodies.
Orphan drugs have a different threshold of evidence re-
quirements compared with nonorphan drugs. In Germany,
orphan drugs (with annual turnover threshold below V50
million) are assumed to have an added benefit.25 We analyzed
the HTA outcomes for NICE, HAS, and G-BA for which EMA
orphan designation was available (125 submissions). A total of 49
SAT-based HTA submissions to these bodies had orphan desig-
nation and 37 (76%) received a positive decision. In comparison,
out of 76 nonorphan submissions, only 27 (37%) were positive.
G-BA gave positive decisions for 87% (12/14) of the orphan drug
submissions and for NICE, 93%(13/14) were positive. In France,
HAS gave 57% (12/21) of orphan submissions a positive decision,
while 7 were classified as negative decisions with ASMR V.
Therefore, statistical tests for significance of outcome differences
would need to account for orphan status as well as other
observed confounding factors.Methodological Approaches for ECs
EC studies can vary in approach, not only by data source but
also by method of comparison (Table 2). Here we present analysis
on whether the ITC used a statistical adjustment or a naive
(nonadjusted) comparison approach.
In the 226 submissions using ECs, only 29% (66) of EC data was
used for an adjusted ITC. This represents only 16% (66/433) of all
SAT submissions. 61%(137) were presumed to use ECs in a naive
comparison context. A prior review of regulatory submissions
found that only 9% (4/43) of non-RCT submissions used an
adjusted ITC.23 In this analysis, the first case of adjusted ITC was
not until 2015 (3, 7% of 2015 submissions) increasing to 29% (30)
in 2019. Over the same period, use of naive ITC reduced as a
proportion of all submissions between 2015 (22, 48%) and 2019
(22, 22%). Prior clinical trials were the single largest source for ECs
and had the highest proportion of adjusted ITC (31%, 32/104).
When all RWD EC sources are combined, 25% (22/87) were used
for adjusted ITC.
Assessing outcomes according to comparison methodology,
no clear differences in overall outcomes were found. Overall,
adjusted ITC submissions had 47% (32/68) positive rate and naive
ITC submissions had 53% (77/144) positive rate. We did see a
difference when analyzing trends in acceptance over the latest 5-
year period by comparing time periods 2015 to 2017 and 2018 to
2019 (Appendix Table 5 in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2021.01.015). We find adjusted ITC
Figure 2. External comparator submissions and outcomes for top 5 HTA bodies by volume, 2011-2019.
-- 5positive decisions increased by 14% (36% in 2015-2017 vs 51% in
2018-2019), whereas naive ITC decisions decreased by 8% (56%
vs 48%).Discussion
To enable access to medicines in situations where RCTs are not
ethical or feasible, an understanding of the landscape and out-
comes for SAT-based submissions is necessary. We found the use
of SAT-based submissions comprises only 5% of total submissions
to HTA bodies; in line with a prior study of 3 HTA key bodies
(NICE, CADTH, and Institut für Qualität und Wirtschaftlichkeit im
Gesundheitswesen [IQWiG]) in which 4% to 6% of submissions
were solely based on non-comparative clinical trial evidence.22Table 2. Method of comparison by type of external comparator (EC
Source of comparator data*, n (%) Method of compa
Adjusted ITC
Prior clinical trial 32 (31%)
Undefined RWD study 8 (22%)
Prior CT & RWD study 12 (34%)
Registry 4 (17%)
Database study 7 (30%)
Chart review 3 (100%)
Grand Total 66 (29%)
RWD indicates Real World Data; ITC, indirect treatment comparison; CT, clinical trial.
*Categories considered as mutually exclusive for purposes of this analysis.However, we found a significant yearly increase over this period,
making this category of submission packages important to
monitor, and this study may support HTA bodies/payers in
developing guidelines and policies to handle these submissions.
To the best of the author’s knowledge, this is the first review of
SAT-based submissions covering all published HTA appraisals and
the use of ECs.
General Trends in EC use
Most SAT-based submissions are in oncology/hemato-oncology
indications, as is expected, based on the current industry trend for
novel targeted therapies and cell and gene therapy approaches for
rare cancers and biomarker-targeted sub-populations.26 However,
we were surprised by the finding that only about half of the SAT-).
rison Total
Naïve ITC Unclear/No EC
62 (60%) 10 (10%) 104
23 (62%) 6 (16%) 37
20 (57%) 3 (9%) 35
17 (71%) 3 (13%) 24
15 (65%) 1 (4%) 23
3
137 (61%) 23 (10%) 226
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data, with only a marginal increase since 2015. However, this is
higher in proportion than that observed for regulatory sub-
missions, on the basis of a previous studies of EMA and FDA
submissions, which reported that 37% of regulatory submissions
contained an EC between 2010 to 2015.8,10,27,28 We expect HTA
bodies to increasingly demand ECs to assess incremental benefit of
new drugs and our research supports this trend. We find
increasing use and acceptance of RWD ECs and decrease in posi-
tive outcomes for submissions with no EC between 2015 to 2019.
The reasons cited for negative HTA decisions commonly mention
missing clinical comparison through a common comparator, lack
of an appropriate comparator, and uncertainly in the new drugs’
clinical benefit.
The statistical methods for external comparison are an ongoing
area of research. In this analysis, we did not see clear differences in
outcomes between adjusted and naive (nonadjusted) ITC methods
overall. However, in the latest 5-year period, we find increasing
use of adjusted EC comparisons and a trend toward increasing
acceptance. This suggests that HTA bodies are beginning to show a
preference for population adjusted unanchored ITC methods such
as STC and MAIC over nonadjusted methods.20,22 Moreover, we
see HTA commentaries for naive EC comparison criticizing a lack
of adjustment for confounders and uncertainty owing to potential
bias in results.
Impact of ECs on HTA Decision-Making
Our study assessed outcomes across 21 HTA bodies and we
acknowledge that this covers the broad array of agencies that have
important differences in terms of maturity, familiarity with
nontraditional evidence packages, the extent to which they make
information publicly available, decision-making remit, and other
country-specific nuances.29,30 In this context, we find that adding
RWD ECs resulted in a higher acceptance rate than observed when
prior trial ECs or no EC data at all were used, which explains the
observed increase in the use of RWD and decrease in the use of
prior clinical trial data between 2014 and 2019. The increasing
availability of RWD and gradual acceptance by HTA and regulatory
bodies has been extensively covered by other commentators.23,31-34
In relation to SAT-based submissions, RWD ECs may be considered
more appropriate as they allow more relevant comparator cohorts
to be constructed and enable the collection of more contemporary
standard of care treatments than prior clinical trials data. However,
we suggest that manufacturers assess other important factors when
designing an EC as there is variation between HTA bodies in
acceptance of RWD. In addition, there are important advantages of
historical trial data to consider such as the availability of a wide
range of endpoints for comparison. Consequently, in our review of
HTA commentaries, we found it challenging to find clear reasons for
higher acceptability for RWD ECs over other types of EC datasets
and this point warrants further study.
For a deeper understanding of country HTA specific factors for
decision making, we evaluated report summaries from key HTA
bodies. For NICE, we see highest acceptance rate (. 80%), which
reflects their acceptance for nontraditional evidence package,
including RWD and familiarity with EC approaches.14,20 However,
most NICE SAT-based submissions were for oncology indications,
which were given restricted access via the cancer drugs fund.
Thus, allowing NICE to carry out further evaluation to manage
uncertainties in clinical benefit. In the France, HAS classified a high
proportion of outcomes as negative with the important caveat that
most negative decisions were ASMR V ratings. This means HAS
could not find any added benefit for the product over existing
treatments, subsequently leading to less favorable pricing. Ourstudy shows, manufacturers that included RWD-based ECs in their
submissions mostly received higher ASMR ratings (Fig. 2). HAS
also issued ASMR V outcomes with an additional request to pro-
vide further study data either from pending clinical trials or RWD
studies, and, thus, this outcome could be considered another type
of conditional approval. These findings suggest a deeper review of
HTA commentaries is justified to give further insights regarding
use of conditional approvals and re-evaluations for SAT-based
submissions.
We know that HTA decisions are influenced by factors such as
unmet need and orphan designation, which makes it a challenge
when trying to correlate the HTA outcome to the strength of the
evidence package. Our results show orphan status is an important
determinant in acceptability of SAT-based submissions, as 58% of
orphan drug submissions receive positive HTA outcomes
compared with 38% of nonorphan drug submissions. HTA bodies
have a higher evidentiary threshold for non-orphan drug sub-
missions, and, therefore, even greater reliance on robust EC data.
Our data show non-orphan submissions with RWD ECs are more
like to receive positive outcomes (71%, 5/7), whereas, submissions
using prior trial ECs or no comparators have mostly negative HTA
outcomes. We are however cautious with this conclusion because
of the low sample size for this calculation.
Limitations
The findings from our study are intended to provide a
description of trends in use of EC data in support HTA decisions,
and not to provide a causal link between the use of RWD or EC
data and the probability of a successful submission. This review
was conducted based on reports from HTA bodies captured sys-
tematically within HTA Accelerator; however, there are important
limitations to consider. First, we are limited to reports published
publicly by HTA bodies. While many HTA bodies are mandated to
publish all appraisals, several HTA bodies do not publish ap-
praisals, such as Japan and Italy. Second, where appraisals are
published, the level of information varies. In particular, the level of
detail on the evidence package related to the SAT and supple-
mentary data including the EC was limited in some published
appraisals. Therefore, the findings of this study may have been
influenced by publication bias. Additionally, while our review aims
to be exhaustive, there is a chance that we did not identify all the
HTA submissions on the basis of pivotal SAT data. This may be the
case in situations where the pivotal trial uses a single-arm design,
but there are also supportive trial data based on a randomized
design, which mean these submissions would not be included in
the current review. Additionally, we did not attempt to examine
all decision drivers for drug acceptance, owing to the large volume
of commentary to review. Additionally, communication between
the manufacturer and the HTA body, which may help to under-
stand the rationale for the evidence package may be missing in the
published reports. Finally, our review intentionally focused on SAT
packages. This is because we understand this to the predominant
design for nonrandomized trials and because SATs can be clearly
identifiable within the HTA Accelerator platform. However, we
acknowledge that other nonrandomized study designs are used
for regulator and HTA submissions.Conclusion
Our analysis describes the complexities in assembling a strong
evidence package for SAT-based submissions for HTA review and
the current variably in HTA outcomes. Consequently, it illustrates
the importance of having a well-considered strategy when relying
on an SAT, robust data collection, and a well-executed analytical
-- 7approach to the indirect treatment comparison. There is little
formal guidance or established best practice for appraisal of HTA
submissions based on SAT evidence, which makes the construc-
tion of comparator cohorts challenging. Careful evaluation of past
HTA decisions and early input from HTA stakeholders are critical
to designing an EC study that can support correct contextualiza-
tion of SATs.Supplemental Materials
Supplementary data associated with this article can be found in the
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